Efficacy, Safety and Pharmacokinetics Study of CPL500036 (PDE10A Inhibitor) in Patients With Schizophrenia
Status:
Recruiting
Trial end date:
2022-05-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the efficacy, safety, tolerability and
pharmacokinetics (PK) properties of CPL500036 compound (PDE10a inhibitor) in patients with an
acute exacerbation of schizophrenia after 28 days of administration..
Phase:
Phase 2
Details
Lead Sponsor:
Celon Pharma SA
Collaborator:
National Center for Research and Development, Poland